Pharmaceuticals News

GENFIT announces its third quarter 2026 financial results1 and provides a corporate update

GENFIT annonce aujourd’hui ses résultats financiers1 du troisième trimestre et fait un point sur les activités de la Société

Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGYAt Week 52, 85.3% of patients...

Les résultats de l’étude ELSPIRE seront présentés en «late-breaking» lors de The Liver Meeting® 2026 et publiés simultanément dans la revue phare de l’AASLD, HEPATOLOGYÀ la semaine 52, 85,3 % des...

FDA assigns a PDUFA target action date of April 9, 2027Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of...

Osteal highlights three APEX-related AAHKS 2026 presentations on 24-month outcomes, systemic antibiotic exposure and recalcitrant PJI.

November 5, 2026 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2026 Highlights Epcoritamab approved in Europe (as TEPKINLY®) and Japan (as EPKINLY®) in combination with...

Press Release – No. 22 / 2026 Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results Copenhagen, Denmark, November 5, 2026 – Zealand Pharma A/S...

Kraig Labs (OTCQB: KBLB) Shipped its first commercial spider silk to a globally recognized sportswear brand for a confidential performance-apparel pilot.

Compounded tirzepatide prescribed through NexLife: $139/mo on a 12-month plan or $169 month to month at every standard dose. Not FDA-approved.